Every material Form 8-K Rallybio Corp has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Rallybio said the closing of its merger with Avenzo Therapeutics, previously expected on November 6, 2026, has been postponed because certain conditions tied to listing the company's shares after the deal have not been met. The company did not deposit funds for a previously announced cash distribution with Computershare on November 5, 2026, so the payment and ex-dividend dates may be delayed.
Merger closing with Avenzo Therapeutics postponed from the expected November 6, 2026 date while listing approvals are sought
Funds for the cash distribution were not deposited with Computershare on November 5, 2026
Previously announced payment date and ex-dividend date for the cash distribution may be delayed; no new dates given
At its November 4, 2026 annual meeting, Rallybio stockholders approved the issuance of Rallybio common stock to Avenzo securityholders under the May 31, 2026 merger agreement, a share issuance the filing says will result in a change of control. Stockholders also approved a reverse stock split at a ratio of 1-for-2 to 1-for-9, a name change to Avenzo Therapeutics, Inc., and an increase in authorized shares. The filing says the board will be reconstituted upon completion of the merger.
Share issuance to Avenzo securityholders approved with 4,506,703 votes for, 15,979 against, 14 abstaining and 267,624 broker non-votes.
Reverse split ratio range of 1-for-2 to 1-for-9 approved; final ratio to be mutually determined by Rallybio and Avenzo.
Authorized common shares to increase from 200,000,000 to 500,000,000; name change to Avenzo Therapeutics, Inc. approved.
Avenzo 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan approved, both effective only upon completion of the merger.
Rallybio's board declared an estimated $82.7 million special cash distribution, or about $13.56 per share, payable to holders of record as of November 5, 2026, in connection with its planned merger with Avenzo Therapeutics. Payment depends on stockholder approval at the November 4, 2026 annual meeting, and the actual amount may be higher or lower than the estimate. Shareholders buying during the due bill period (November 4 through November 6, 2026) will receive the distribution, while sellers will not.
Estimated cash distribution of $82.7 million, or $13.56 per share, based on 6,378,168 shares and equivalents outstanding as of October 21, 2026
Record Date November 5, 2026; ex-dividend date expected November 6, 2026; distribution scheduled for November 13, 2026
Payment conditioned on Required Company Stockholder Vote at the annual meeting at 10:00 a.m. Eastern Time on November 4, 2026
Merger closing expected on or about November 6, 2026
Rallybio's Chief Financial Officer, Jonathan Lieber, will move to part-time employment effective September 15, 2026, but will remain CFO and Principal Financial Officer with the same duties and authority. His employment will end when the pending business combination with Avenzo Therapeutics closes, unless it is terminated earlier.
Part-time transition effective September 15, 2026; he keeps the CFO and principal financial officer titles
Base salary of $420,000 after the transition, with benefit plan participation
No annual bonus for 2026 or any later year he is employed
Employment ends at the closing of the Avenzo merger agreement dated May 31, 2026; severance follows under his existing employment agreements
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Rallybio Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →